// App-Quantinova.ai

: A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL)

Researchers

Presenter

  • Michael Dickinson

Principal Investigators

  • Brian J.P Huntly

  • Carlos Fernndez De Larrea

  • Raul Cordoba

  • Maria-Victoria Mateos

  • Adrin Alegre

  • Won-Seog Kim

  • Jin Seok Kim

  • Mark Dawson

  • Paul Sung-Hao Yeh

  • Faisal Basheer

  • Paolo Gallipoli

  • Aristeidis Chaidos

  • Alejandro Martn

  • Thierry Horner

  • James Winnberg

  • Lijoy K Mathew

  • Jeffrey Botbyl

  • Natalie Karpinich

  • Brandon E. Kremer

  • Arindam Dhar

  • Anastasios Karadimitris

Medical Centers

  • Peter MacCallum Cancer Center, Royal Melbourne Hospital, and University of Melbourne ,Melbourne,Australia

  • Department of Medicine, Division of Rheumatology, University of Michigan School of Medicine, Ann Arbor, MI

  • University of Colorado Hospital, Aurora, CO

  • Department of Radiology, Addenbrooke's Hospital, Cambridge, United Kingdom

  • Servei d'Hematologia, Hospital Clinic de Barcelona, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain

  • Fundacion Jimenez Diaz University Hospital, Madrid, Spain

  • University Hospital of Salamanca, Salamanca, Spain

  • Hospital Universitario La Paz, Madrid, Spain

  • Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  • Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Seoul, Republic of Korea

  • Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea, Republic of.

  • Peter MacCallum Cancer Centre, Melbourne, St Vincent’s...

  • Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Cambridge, United Kingdom

  • University of Cambridge, Cambridge, United Kingdom

  • Centre for Haematology, Department of Medicine, Imperial College London, London, United Kingdom

  • Hematology Department, Hospital Universitario de Salamanca and IBSAL, CIBERONC, Salamanca, Spain

  • GlaxoSmithKline, Collegeville, PA

  • GlaxoSmithKline, Douglassville, PA

  • GlaxoSmithKline, Collegeville, PA

  • Centre for Haematology, Department of Medicine, Imperial College London, London, United Kingdom

Locations

  • Australia

  • United States

  • United Kingdom

  • Spain

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non-Hodgkin's Lymphoma

Biomarkers

  • Nucleoside diphosphate kinase A

Drug/Treatment

  • Molibresib

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Open Label

  • Dose Escalation

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved